Alps Advisors Inc Glycomimetics Inc Transaction History

Alps Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 05, 2020	SELL	$2.06 - $3.76 $162,383 - $296,389	-78,827 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$1.83 - $5.41 $16,825 - $49,739	-9,194 Reduced 10.45%	78,827 $180,000
Q4 2019 Feb 07, 2020	BUY	$4.03 - $6.5 $7,487 - $12,077	1,858 Added 2.16%	88,021 $466,000
Q3 2019 Nov 04, 2019	SELL	$2.8 - $12.85 $11,790 - $54,111	-4,211 Reduced 4.66%	86,163 $371,000
Q2 2019 Aug 07, 2019	SELL	$10.6 - $13.12 $146,470 - $181,292	-13,818 Reduced 13.26%	90,374 $1.08 Million
Q1 2019 May 01, 2019	BUY	$9.96 - $13.44 $44,889 - $60,574	4,507 Added 4.52%	104,192 $1.3 Million
Q4 2018 Feb 04, 2019	BUY	$8.47 - $14.71 $198,960 - $345,537	23,490 Added 30.83%	99,685 $944,000
Q3 2018 Oct 25, 2018	BUY	$13.7 - $17.12 $199,143 - $248,856	14,536 Added 23.57%	76,195 $1.1 Million
Q2 2018 Aug 02, 2018	BUY	$14.63 - $19.19 $345,399 - $453,056	23,609 Added 62.05%	61,659 $995,000
Q2 2018 Jul 25, 2018	SELL	$14.63 - $19.19 $117,098 - $153,596	-8,004 Reduced 17.38%	38,050 $639,000
Q1 2018 May 01, 2018	BUY	$16.06 - $25.35 $128,544 - $202,901	8,004 Added 21.04%	46,054 $747,000
Q4 2017 Feb 05, 2018	BUY	$10.51 - $17.22 $399,905 - $655,221	38,050	38,050 $639,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.